ZYVERSA THERAPEUTICS, INC. — Cash Flow Charts
11 quarters of history · ending 2025-09-30 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↑+53.1% +$2M
$-2M
Free Cash Flow↑+53.1% +$2M
$-2M
Investing Cash Flow
—
Financing Cash Flow↑+187.5% +$1M
$2M
Stock-Based Comp↓-53.9% -$87K
$74K
D&A↓-100.0% -$3K
$0
SBC Allocated Expense↓-53.9% -$87K
$74K
SBC Unrecognized Cost
$127K